In 2016, obeticholic acid became the first new licensed therapy for primary biliary cholangitis in >20 years. This therapeutic came at a time of improved disease understanding from biliary and ...
Zacks Investment Research on MSN
Planet Labs PBC (PL) could find a support soon, here's why you should buy the stock now
Shares of Planet Labs PBC (PL) have been struggling lately and have lost 7% over the past week. However, a hammer chart ...
Learn more William Spencer Marshall, co-founder and Chief Executive Officer of Planet Labs PBC (NYSE:PL), disclosed a sale of ...
We recently published an article titled Why These 15 Defense Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Planet Labs PBC (NYSE:PL) stands against the ...
The average one-year price target for Planet Labs PBC (NYSE:PL) has been revised to $37.37 / share, a decrease of 14.00% from the prior estimate of $43.45 dated August 25, 2026. These figures ...
September is the perfect time to turn up the volume on conversations about Primary Biliary Cholangitis (PBC) and the symptoms people living with it experience, in support of PBC Awareness Month.
Planet Labs PBC (NYSE: PL), a leading provider of daily data and insights about change on Earth, today released first light images from its latest Pelican launch, including the Swedish Armed Forces ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results